Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZD1839 (IRESSA) in Hormone Refractory Prostate Cancer
NCT00025116Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Apr 2001
- Primary completion
- Jun 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of gefitinib in prostate cancer (PCa) (2 arms), sponsored by Canadian Cancer Trials Group. Primary endpoints: Objective Response Rate, Prostate-Specific Antigen Response and 3 more. Started Apr 2001; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00025116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025116.